ReviewCancer prevention research (Philadelphia, Pa.)2014
Cancer immunoprevention--the next frontier.
Review in Cancer prevention research (Philadelphia, Pa.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 21 citations in OpenAlex.
- Review
- Microtube Array Membrane (MTAM)-Based Encapsulated Cell Therapy for Cancer Treatment.Membranes · 2020Article
- Cancer Vaccines Co-Targeting HER2/Neu and IGF1R.Cancers · 2019Article
- Article
- Cancer immunoprevention: from mice to early clinical trials.BMC immunology · 2018Review
- Effects of dexmedetomidine on inflammatory factors, T lymphocyte subsets and expression of NF-κB in peripheral blood mononuclear cells in patients receiving radical surgery of colon carcinoma.Oncology letters · 2018Article
- Chemoprevention of Preclinical Breast and Lung Cancer with the Bromodomain Inhibitor I-BET 762.Cancer prevention research (Philadelphia, Pa.) · 2018Article
- Cancer Immunotherapy, Part 3: Challenges and Future Trends.P & T : a peer-reviewed journal for formulary management · 2017Article
- Maternal Immunization: New Perspectives on Its Application Against Non-Infectious Related Diseases in Newborns.Vaccines · 2017Review
- Cancer Immunotherapy, Part 2: Efficacy, Safety, and Other Clinical Considerations.P & T : a peer-reviewed journal for formulary management · 2017Article
- Cancer Prevention: Lessons Learned and Future Directions.Trends in cancer · 2016Review
- The triterpenoid CDDO-imidazolide reduces immune cell infiltration and cytokine secretion in the KrasG12D;Pdx1-Cre (KC) mouse model of pancreatic cancer.Carcinogenesis · 2016Article
- Antitumor immunization of mothers delays tumor development in cancer-prone offspring.Oncoimmunology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Cancer immunotherapy is a rapidly developing field, but limited in its success by a high tumor burden and immune tolerance. In contrast, immunoprevention has the potential to prevent cancer before the development of immune tolerance, and to prevent cancer recurrence in the setting of minimal residual disease. Although immunoprevention for viral-induced cancers has been successful in the setting of hepatitis B and human papillomavirus vaccination, primary prevention of nonviral-induced cancers is in its infancy. In contrast, prevention of cancer recurrence after adjuvant treatment (secondary prevention) is gaining steam. This review provides an overview of the scope of research in cancer immunoprevention over the last three years and directions for future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.